

Joel Pekow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4689274/publications.pdf>

Version: 2024-02-01

40
papers

1,577
citations

361413

20
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

2940
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. <i>Journal of Clinical Investigation</i> , 2013, 123, 3983-3996.	8.2	270
2	The emerging role of miRNAs in inflammatory bowel disease: a review. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 4-22.	3.2	136
3	EGFR Signals Downregulate Tumor Suppressors miR-143 and miR-145 in Western Diet-Associated Murine Colon Cancer: Role of G1 Regulators. <i>Molecular Cancer Research</i> , 2011, 9, 960-975.	3.4	114
4	Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 152-157.	1.9	110
5	Real-World Experience with Tofacitinib in IBD at a Tertiary Center. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1945-1951.	2.3	80
6	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 113-120.	4.7	78
7	A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. <i>Nature Communications</i> , 2020, 11, 6161.	12.8	76
8	miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. <i>Clinical Cancer Research</i> , 2017, 23, 5281-5291.	7.0	73
9	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 104-110.	4.4	60
10	Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 68-74.	4.4	45
11	The Renin-Angiotensin System Mediates EGF Receptor-Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5848-5859.	7.0	40
12	ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 549-561.	7.0	40
13	Gene Signature Distinguishes Patients with Chronic Ulcerative Colitis Harboring Remote Neoplastic Lesions. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 461-470.	1.9	39
14	Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G179-G187.	3.4	39
15	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2017, 12, e0182900.	2.5	39
16	Wnt- β -catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. <i>Nature Immunology</i> , 2021, 22, 471-484.	14.5	39
17	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 269-275.	1.0	36
18	Clinical Presentation and Disease Course of Inflammatory Bowel Disease Differs by Race in a Large Tertiary Care Hospital. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2228-2235.	2.3	34

#	ARTICLE	IF	CITATIONS
19	Linear and circular CDKN2B-AS1 expression is associated with Inflammatory Bowel Disease and participates in intestinal barrier formation. <i>Life Sciences</i> , 2019, 231, 116571.	4.3	33
20	Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1938-1944.	2.3	23
21	miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1328-1337.	1.9	22
22	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2634-2640.	1.9	20
23	Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G722-G733.	3.4	18
24	Northern Latitude but Not Season Is Associated with Increased Rates of Hospitalizations Related to Inflammatory Bowel Disease: Results of a Multi-Year Analysis of a National Cohort. <i>PLoS ONE</i> , 2016, 11, e0161523.	2.5	17
25	IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 884-893.	1.3	15
26	A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 933-940.	3.7	12
27	Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. <i>Epigenetics</i> , 2021, 16, 1317-1334.	2.7	10
28	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. <i>Intestinal Research</i> , 2022, 20, 240-250.	2.6	10
29	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis</i> 360, 2020, 2, otaa039.	1.1	8
30	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1365-1372.	3.7	8
31	Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis. <i>Oncotarget</i> , 2018, 9, 20709-20720.	1.8	7
32	Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease. <i>Intestinal Research</i> , 2022, 20, 303-312.	2.6	7
33	Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. <i>Surgical Infections</i> , 2018, 19, 785-791.	1.4	6
34	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2090-2095.	2.8	6
35	Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 433-448.	1.5	4
36	Is RXR α Crucially Involved in Intestinal Inflammation?. <i>Digestive Diseases and Sciences</i> , 2014, 59, 702-703.	2.3	2

#	ARTICLE	IF	CITATIONS
37	Association Between Higher Predicted Serum Vitamin D Levels and Reduced Incidence of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2012, 143, e28.	1.3	1
38	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Reply Letter to Elia et al.. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e94-e94.	1.9	0
39	Editorial: time to modify practice and use the modified Rutgeerts' score. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 754-755.	3.7	0
40	Editorial: response to tofacitinib is associated with high rates of long-term treatment persistence. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1222-1223.	3.7	0